Latest Financial Results

Q1 2023

Quarterly Results

Quarter Ended Mar 31, 2023

Sign up for email alerts

Be the first to receive breaking news

Sign up today

Stock Information Data is 15 minutes delayed

ContraFect Corporation — Common Stock Nasdaq: CFRX
Price
Change
Market Cap
Volume

Company Overview

ContraFect is a clinical-stage biotechnology company focused on discovering and developing biologic therapies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our platform of direct lytic agents (DLAs), which include lysins and amurin peptides. We believe DLAs provide the opportunity to make meaningful improvements to clinical outcomes and to change the treatment paradigm for patients infected with antibiotic-resistant bacteria.  Our initial product candidates are new agents to treat lethal, resistant infections such as methicillin-resistant Staph aureus (MRSA) and Gram-negative pathogens like multi-drug resistant (MDR) Pseudomonas aeruginosa.